Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Syros Pharmaceuticals (SYRS)
NASDAQ:SYRS
SYRS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.16 - $7.96
Previous CloseN/A
Volume1.14M
Average Volume (3M)1.29M
Market Cap
$4.72M
Enterprise Value$86.52M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.83
Next Earnings
Mar 06, 2025EPS Estimate
-0.72Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.03
Shares Outstanding26,832,457
10 Day Avg. Volume1,390,737
30 Day Avg. Volume1,287,613
Standard Deviation0.35
R-Squared0.04
Alpha-0.05
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)12.19
Price to Cash Flow (P/CF)-0.10
P/FCF Ratio0.00
Enterprise Value/Market Cap18.34
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit11.26
Enterprise Value/Ebitda-0.95
Forecast
1Y Price Target
$1.00Price Target Upside488.24% Upside
Rating ConsensusHold
Number of Analyst Covering0
---
Syros Pharmaceuticals News
---
Bulls Say, Bears Say
Bulls Say
Market OpportunityManagement highlighted the large commercial opportunity for tamibarotene in RARA-positive HR-MDS, with a market opportunity of ~$1.6Bn, >$800MM in RARA positive patients.
Safety ProfileThe potential for tamibarotene is compelling both in terms of potential efficacy but also the candidate’s well tolerated safety profile.
Therapeutic PotentialTamibarotene would be the first targeted therapy for the patient population, addressing the ~50% of patients with RARA overexpression.
Bears Say
Clinical Trial FailureThe Phase 3 SELECT-MDS-1 trial failed to meet its primary endpoint of complete response rate.
Financial StrainThe failure to meet the primary endpoint in the SELECT-MDS-1 trial triggers an event of default under the secured loan agreement with Oxford Finance LLC.
Stock PerformanceThe stock traded down about 86% in the aftermarket, reflecting a significant decline in valuation.
---
Ownership Overview
10.40% Insiders
4.44% Mutual Funds
18.02% Other Institutional Investors
66.01% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
SYRS FAQ
What was Syros Pharmaceuticals’s price range in the past 12 months?
Syros Pharmaceuticals lowest stock price was $0.16 and its highest was $7.96 in the past 12 months.
What is Syros Pharmaceuticals’s market cap?
Syros Pharmaceuticals’s market cap is $4.72M.
When is Syros Pharmaceuticals’s upcoming earnings report date?
Syros Pharmaceuticals’s upcoming earnings report date is Mar 06, 2025 which is in 12 days.
How were Syros Pharmaceuticals’s earnings last quarter?
Syros Pharmaceuticals released its earnings results on Oct 31, 2024. The company reported -$0.16 earnings per share for the quarter, beating the consensus estimate of -$0.676 by $0.516.
Is Syros Pharmaceuticals overvalued?
According to Wall Street analysts Syros Pharmaceuticals’s price is currently Undervalued.
Does Syros Pharmaceuticals pay dividends?
Syros Pharmaceuticals does not currently pay dividends.
What is Syros Pharmaceuticals’s EPS estimate?
Syros Pharmaceuticals’s EPS estimate is -0.72.
How many shares outstanding does Syros Pharmaceuticals have?
Syros Pharmaceuticals has 26,832,457 shares outstanding.
What happened to Syros Pharmaceuticals’s price movement after its last earnings report?
Syros Pharmaceuticals reported an EPS of -$0.16 in its last earnings report, beating expectations of -$0.676. Following the earnings report the stock price went up 0.398%.
Which hedge fund is a major shareholder of Syros Pharmaceuticals?
Currently, no hedge funds are holding shares in SYRS
---
Company Description
Syros Pharmaceuticals
Syros Pharmaceuticals, Inc. engages in the development of novel gene control therapies for cancer and other diseases. It has developed a proprietary platform that is designed to systematically and efficiently analyse unexploited region of DNA in human disease tissue to identify and drug novel targets linked to genomically defined patient populations. The firm focuses on developing treatments for cancer and immune mediated diseases and is building a pipeline of gene control medicines. The company was founded by Richard A. Young, Nathanael S. Gray and James E. Bradner on November 9, 2011 and is headquartered in Cambridge, MA.
---
SYRS Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call conveyed a cautiously optimistic outlook, emphasizing the advancement of tamibarotene and its significant market potential, alongside improved financial metrics. However, the lack of revenue and decreased cash reserves present notable concerns.Read More>---
SYRS Stock 12 Month Forecast
Average Price Target
$1.00
▲(488.24% Upside)
Technical Analysis
Best Analysts Covering SYRS
1 Year
1 Year Success Rate
2/12 ratings generated profit
1 Year Average Return
-55.86%
reiterated a buy rating 4 months ago
Copying Edward Tenthoff's trades and holding each position for 1 Year would result in 16.67% of your transactions generating a profit, with an average return of -55.86% per trade.
---